Floatz logo

DENTALFLUORO

Metastatic Prostate Cancer

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
73/ 100

Competitive context

251 Active assets in the Metastatic Prostate Cancer cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Mayo Clinic
Phase 4BBB
Fluciclovine
VA Greater Los Angeles Healthcare System
Phase 4BBB
LEUPROLIDE
Mayo Clinic
Phase 4BBB
PREDNISONE TABLETS
Mayo Clinic
Phase 4BB
Abiraterone Acetate
Mayo Clinic
Phase 4BB

View all 50 →

Same molecule, other indications

DENTALFLUORO is also rated in:

metastatic carcinoma in the boneDormant
BB
Indicative ·
66 / 100
View asset →
Bone Metastases From Breast or Prostate CancerDormant
B
Indicative ·
63 / 100
View asset →
prostate neoplasmDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →